Bharat Biotech's cholera vaccine successfully completes Phase-III trials

Bharat Biotech's oral Cholera Vaccine, Hillchol, has successfully completed phase III clinical trials, demonstrating non-inferiority against Ogawa and Inaba serotypes in Indian adults and children. The study involved 1,800 participants across various age groups and ten clinical sites in India. With a production capacity of 200 million doses, Hillchol aims to address the global OCV shortage.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fBnxjT1
via IFTTT